Commentary|Videos|July 31, 2024
Real-World Safety Data for BTK Inhibitors in CLL from EHA 2024
Author(s)Mazyar Shadman, MD, MPH, Marc S. Hoffmann, MD
Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss real-world safety data for BTK inhibitors in chronic lymphocytic leukemia from EHA 2024.
Advertisement
Episodes in this series
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Advertisement
Advertisement
Trending on OncLive
1
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma
4
Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma
5